Cantor Fitzgerald Lowers Earnings Forecast for Scholar Rock

Analysts at Cantor Fitzgerald have revised their earnings projections for Scholar Rock Holding Corporation (NASDAQ: SRRK), forecasting a decline in the company’s financial performance for fiscal year 2025. In a research note released on November 17, 2023, analyst E. Schmidt now predicts that Scholar Rock will report earnings of ($3.51) per share, a decrease from the previous estimate of ($3.41). This revision contrasts with the consensus estimate for the current year, which stands at ($2.42) per share.

In their most recent earnings report, Scholar Rock announced on November 14, 2023, that it had posted an earnings per share (EPS) of ($0.90) for the quarter. This figure fell short of analysts’ expectations, which anticipated an EPS of ($0.88), marking a notable decline from the ($0.66) EPS recorded during the same quarter last year.

Stock Performance and Market Activity

Following the announcement, Scholar Rock’s stock opened at $38.02 on Wednesday, demonstrating a decrease of 4.2%. The company currently maintains a market capitalization of $3.65 billion, with a price-to-earnings (PE) ratio of -13.07 and a beta of 0.79. Notably, Scholar Rock’s debt-to-equity ratio is 0.21, while both its current and quick ratios are recorded at 6.33. The stock has experienced a 52-week range, with a low of $22.71 and a high of $46.98.

Recent activity among institutional investors indicates a shift in positions. CWM LLC increased its holdings in Scholar Rock by 152.8% in the first quarter, now owning 996 shares valued at $32,000. In addition, Ramirez Asset Management Inc. acquired a new stake worth approximately $37,000 in the third quarter, while Federated Hermes Inc. invested $71,000 in new shares during the same period.

Insider Transactions and Ownership

In other corporate developments, Katie Peng, a director at Scholar Rock, sold 1,006 shares on September 16, 2023, at an average price of $32.53, totaling $32,725.18. After this transaction, her remaining shares are valued at approximately $1,103,222.42. This sale reflects a 2.88% reduction in her holdings.

Similarly, insider Mo Qatanani sold 3,353 shares on September 22, 2023, for $102,836.51. Following this transaction, Qatanani’s ownership stands at 108,964 shares, estimated to be worth around $3,341,925.88. In total, insiders have sold 7,537 shares in the last three months, amounting to $242,088. Insiders currently hold 13.30% of the company’s stock.

Scholar Rock focuses on the discovery and development of therapies aimed at treating serious diseases influenced by protein growth factors. The company’s leading products include Apitegromab, currently in Phase 3 clinical trials for spinal muscular atrophy, and SRK-181, which has successfully completed Phase 1 trials targeting cancers resistant to existing therapies.

As Scholar Rock continues to navigate its financial landscape, the updates from Cantor Fitzgerald serve as a critical indicator for investors monitoring the company’s performance and future potential in the biopharmaceutical sector.